<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01303445</url>
  </required_header>
  <id_info>
    <org_study_id>9.197</org_study_id>
    <nct_id>NCT01303445</nct_id>
  </id_info>
  <brief_title>Drug-drug Interaction Study of Aggrenox and Omeprazole in Normal Volunteers</brief_title>
  <official_title>Drug-drug Interaction Study of the Effect of Omeprazole 80 mg q.d. at Steady State on the Pharmacokinetics and Pharmacodynamics of Aggrenox® Every 12 Hours at Steady State in Healthy Male and Female Volunteers (an Open-label, Randomised, Crossover Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of the current study is to investigate if a drug-drug interaction occurs with
      the administration of omeprazole 80 mg q.d. at steady state on the pharmacokinetics of
      dipyridamole and the pharmacodynamics of ASA-induced platelet aggregation inhibition
      (components of Aggrenox®) when administered every 12 hours at steady state.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose:
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Dipyridamole Maximum Concentration (Cmax)</measure>
    <time_frame>7 days</time_frame>
    <description>Maximum measured concentration of dipyridamole in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Dipyridamole Area Under Plasma Concentration-time Curve From Zero to 12 Hours (AUC0-12)</measure>
    <time_frame>7 days</time_frame>
    <description>Area under the concentration time curve of the analyte in plasma from 0 to 12 hours at steady state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inhibition of Platelet Aggregation at 4 Hours Post Dose (IPA4)</measure>
    <time_frame>7 days</time_frame>
    <description>IPA4 equals the platelet aggregation measured 4 hours post dose divided by the platelet aggregation measured at baseline (multiplied by 100).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Dipyridamole Minimum Concentration (Cmin)</measure>
    <time_frame>7 days</time_frame>
    <description>Minimum measured concentration of dipyridamole in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inhibition of Platelet Aggregation at 12 Hours Post Dose (IPA12)</measure>
    <time_frame>7 days</time_frame>
    <description>IPA12 equals the platelet aggregation measured 12 hours post dose divided by the platelet aggregation measured at baseline (multiplied by 100).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Peak-to-trough Fluctuation (%PTF)</measure>
    <time_frame>7 days</time_frame>
    <description>PTF = 100*((Cmax-Cmin)/Cavg) where Cavg=(AUC0-12)/12.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aggrenox alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aggrenox and omeprazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Omeprazole alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aggrenox and omeprazole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aggrenox alone</intervention_name>
    <description>Aggrenox 1 capsule twice daily for 7 days</description>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aggrenox and omeprazole</intervention_name>
    <description>Aggrenox 1 capsule twice daily and omeprazole 80mg once daily for 7 days</description>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aggrenox and omeprazole</intervention_name>
    <description>Aggrenox 1 capsule twice daily and omeprazole 80mg once daily for 7 days</description>
    <arm_group_label>Treatment D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole alone</intervention_name>
    <description>omeprazole 80 once daily for 7 days</description>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy males and females according to the following criteria:

             Based upon a complete medical history, including the physical examination, vital signs
             (blood pressure(BP), pulse rate (PR)), 12-lead ECG, clinical laboratory tests

          2. BMI &gt;18.5 and BMI &lt;32 kg/m2 (Body Mass Index)

        Exclusion criteria:

          1. Any finding of the medical examination (including BP, PR and ECG) deviating from
             normal and of clinical relevance in the opinion of the PI

          2. Any evidence of a clinically relevant concomitant disease

          3. Clinically significant gastrointestinal, hepatic, renal, respiratory, cardiovascular,
             metabolic, immunological, hormonal, or hematologic (including a history of abnormal
             bruising) disorders in the opinion of the PI

          4. Surgery of the gastrointestinal tract that might impair drug absorption

          5. Clinically significant diseases of the central nervous system (such as epilepsy) or
             psychiatric disorders or neurological disorders

          6. History of relevant orthostatic hypotension, fainting spells or blackouts.

          7. Chronic or relevant acute infections

          8. History of relevant allergy/hypersensitivity (including allergy to study drugs or its
             excipients, or reactions to related drugs [e.g., non-steroidal anti-inflammatory
             drugs])

          9. Intake of drugs with a long half-life (¿24 hours) within one month, or less than 10
             half lives of the respective drug, prior to study drug administration or during the
             trial

         10. Use of drugs which might reasonably influence the results of the trial (including OTC
             antacids) based on the knowledge at the time of protocol preparation within 14 days
             prior to administration or during the trial

         11. Participation in another trial with an investigational drug within two months prior to
             administration or during the trial

         12. Tobacco use within the 90 days prior to check-in and throughout the study

         13. Alcohol abuse within the past 2 years

         14. Drug abuse within the past 2 years

         15. Blood donation or other significant blood loss within 56 days (inclusive) prior to
             screening, or plasma donation within 7 days (inclusive) prior to study drug
             administration, or during the trial

         16. Excessive physical activities (within one week prior to first drug administration or
             during the trial)

         17. Any laboratory value outside the reference range that is of clinical relevance in the
             opinion of the PI; including positive virology, or urine drug screen, or positive
             fecal occult blood test

         18. Inability to comply with dietary regimen of trial site

         19. In the opinion of the investigator it would be in the best interest of the subject to
             be excluded from participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>9.197.001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2011</study_first_submitted>
  <study_first_submitted_qc>February 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2011</study_first_posted>
  <results_first_submitted>April 24, 2012</results_first_submitted>
  <results_first_submitted_qc>July 23, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 24, 2012</results_first_posted>
  <last_update_submitted>November 27, 2013</last_update_submitted>
  <last_update_submitted_qc>November 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2013</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Aspirin, Dipyridamole Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ABCD Sequence</title>
          <description>Aggrenox/Aggrenox+Omeprazole/Omeprazole/Aggrenox+Omeprazole</description>
        </group>
        <group group_id="P2">
          <title>CDAB Sequence</title>
          <description>Omeprazole/Aggrenox+Omeprazole/Aggrenox/Aggrenox+Omeprazole</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout (14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Third Intervention (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Fourth Intervention (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-up Period (14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.3" lower_limit="20" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black / African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.69" lower_limit="55.2" upper_limit="101.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kilograms per square meter</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.81" lower_limit="20.45" upper_limit="31.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Plasma Dipyridamole Maximum Concentration (Cmax)</title>
        <description>Maximum measured concentration of dipyridamole in plasma</description>
        <time_frame>7 days</time_frame>
        <population>The pharmacokinetic data set (PK set) and the pharmacodynamic data set (PD set) include all treated subjects with data that do not have a relevant protocol violation (relevant to PK or PD). No data collected for Omeprazole arm since no plasma dipyridamole was expected for this treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Aggrenox Alone BID</title>
            <description>Aggrenox (aspirin/extended release dipyridamole) 25mg/200mg capsules BID (twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Aggrenox BID Plus Omeprazole QD Following Aggrenox Alone</title>
            <description>Aggrenox 25mg/200mg capsules BID plus Omeprazole 40mg QD (once daily) following Aggrenox alone</description>
          </group>
          <group group_id="O3">
            <title>Aggrenox BID Plus Omeprazole QD Following Omeprazole Alone</title>
            <description>Aggrenox 25mg/200mg capsules BID plus Omeprazole 40mg QD (once daily) following Omeprazole alone</description>
          </group>
          <group group_id="O4">
            <title>Omeprazole Alone QD</title>
            <description>Omeprazole 40mg QD (once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Dipyridamole Maximum Concentration (Cmax)</title>
          <description>Maximum measured concentration of dipyridamole in plasma</description>
          <population>The pharmacokinetic data set (PK set) and the pharmacodynamic data set (PD set) include all treated subjects with data that do not have a relevant protocol violation (relevant to PK or PD). No data collected for Omeprazole arm since no plasma dipyridamole was expected for this treatment.</population>
          <units>nanogram/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2750" spread="30.4"/>
                    <measurement group_id="O2" value="2550" spread="27.5"/>
                    <measurement group_id="O3" value="2550" spread="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Aggrenox + Omeprazole following Omeprazole versus Aggrenox alone</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence was established if the 90% confidence interval of the mean ratio fell within the 80 to 125% target range.</non_inferiority_desc>
            <param_type>Percent Mean Ratio</param_type>
            <param_value>92.03</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>86.95</ci_lower_limit>
            <ci_upper_limit>97.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Aggrenox + Omeprazole following Aggrenox versus Aggrenox alone</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence was established if the 90% confidence interval of the mean ratio fell within the 80 to 125% target range.</non_inferiority_desc>
            <param_type>Percent Mean Ratio</param_type>
            <param_value>92.30</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>87.76</ci_lower_limit>
            <ci_upper_limit>97.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Dipyridamole Area Under Plasma Concentration-time Curve From Zero to 12 Hours (AUC0-12)</title>
        <description>Area under the concentration time curve of the analyte in plasma from 0 to 12 hours at steady state</description>
        <time_frame>7 days</time_frame>
        <population>The pharmacokinetic data set (PK set) and the pharmacodynamic data set (PD set) include all treated subjects with data that do not have a relevant protocol violation (relevant to PK or PD). No data collected for Omeprazole arm since no plasma dipyridamole was expected for this treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Aggrenox Alone BID</title>
            <description>Aggrenox (aspirin/extended release dipyridamole) 25mg/200mg capsules BID (twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Aggrenox BID Plus Omeprazole QD Following Aggrenox Alone</title>
            <description>Aggrenox 25mg/200mg capsules BID plus Omeprazole 40mg QD (once daily) following Aggrenox alone</description>
          </group>
          <group group_id="O3">
            <title>Aggrenox BID Plus Omeprazole QD Following Omeprazole Alone</title>
            <description>Aggrenox 25mg/200mg capsules BID plus Omeprazole 40mg QD (once daily) following Omeprazole alone</description>
          </group>
          <group group_id="O4">
            <title>Omeprazole Alone QD</title>
            <description>Omeprazole 40mg QD (once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Dipyridamole Area Under Plasma Concentration-time Curve From Zero to 12 Hours (AUC0-12)</title>
          <description>Area under the concentration time curve of the analyte in plasma from 0 to 12 hours at steady state</description>
          <population>The pharmacokinetic data set (PK set) and the pharmacodynamic data set (PD set) include all treated subjects with data that do not have a relevant protocol violation (relevant to PK or PD). No data collected for Omeprazole arm since no plasma dipyridamole was expected for this treatment.</population>
          <units>(nanogram/milliliter)*hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17100" spread="33.7"/>
                    <measurement group_id="O2" value="16700" spread="28.4"/>
                    <measurement group_id="O3" value="16500" spread="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Aggrenox + Omeprazole following Omeprazole versus Aggrenox alone</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence was established if the 90% confidence interval of the mean ratio fell within the 80 to 125% target range.</non_inferiority_desc>
            <param_type>Percent Mean Ratio</param_type>
            <param_value>96.38</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>90.96</ci_lower_limit>
            <ci_upper_limit>102.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Aggrenox + Omeprazole following Aggrenox versus Aggrenox alone</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence was established if the 90% confidence interval of the mean ratio fell within the 80 to 125% target range.</non_inferiority_desc>
            <param_type>Percent Mean Ratio</param_type>
            <param_value>97.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>93.26</ci_lower_limit>
            <ci_upper_limit>100.95</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Inhibition of Platelet Aggregation at 4 Hours Post Dose (IPA4)</title>
        <description>IPA4 equals the platelet aggregation measured 4 hours post dose divided by the platelet aggregation measured at baseline (multiplied by 100).</description>
        <time_frame>7 days</time_frame>
        <population>The pharmacokinetic data set (PK set) and the pharmacodynamic data set (PD set) include all treated subjects with data that do not have a relevant protocol violation (relevant to PK or PD). No data collected for Omeprazole arm since no platelet inhibition was expected for this treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Aggrenox Alone BID</title>
            <description>Aggrenox (aspirin/extended release dipyridamole) 25mg/200mg capsules BID (twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Aggrenox BID Plus Omeprazole QD Following Aggrenox Alone</title>
            <description>Aggrenox 25mg/200mg capsules BID plus Omeprazole 40mg QD (once daily) following Aggrenox alone</description>
          </group>
          <group group_id="O3">
            <title>Aggrenox BID Plus Omeprazole QD Following Omeprazole Alone</title>
            <description>Aggrenox 25mg/200mg capsules BID plus Omeprazole 40mg QD (once daily) following Omeprazole alone</description>
          </group>
          <group group_id="O4">
            <title>Omeprazole Alone QD</title>
            <description>Omeprazole 40mg QD (once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Inhibition of Platelet Aggregation at 4 Hours Post Dose (IPA4)</title>
          <description>IPA4 equals the platelet aggregation measured 4 hours post dose divided by the platelet aggregation measured at baseline (multiplied by 100).</description>
          <population>The pharmacokinetic data set (PK set) and the pharmacodynamic data set (PD set) include all treated subjects with data that do not have a relevant protocol violation (relevant to PK or PD). No data collected for Omeprazole arm since no platelet inhibition was expected for this treatment.</population>
          <units>percent of baseline platelet aggregation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.89" spread="2.74"/>
                    <measurement group_id="O2" value="96.34" spread="4.21"/>
                    <measurement group_id="O3" value="97.02" spread="2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Aggrenox + Omeprazole following Omeprazole versus Aggrenox alone</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence was established if the 90% confidence interval of the mean ratio fell within the 80 to 125% target range.</non_inferiority_desc>
            <param_type>Percent Mean Ratio</param_type>
            <param_value>99.02</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>98.32</ci_lower_limit>
            <ci_upper_limit>99.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Aggrenox + Omeprazole following Aggrenox versus Aggrenox alone</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence was established if the 90% confidence interval of the mean ratio fell within the 80 to 125% target range.</non_inferiority_desc>
            <param_type>Percent Mean Ratio</param_type>
            <param_value>98.42</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>97.66</ci_lower_limit>
            <ci_upper_limit>99.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Dipyridamole Minimum Concentration (Cmin)</title>
        <description>Minimum measured concentration of dipyridamole in plasma</description>
        <time_frame>7 days</time_frame>
        <population>The pharmacokinetic data set (PK set) and the pharmacodynamic data set (PD set) include all treated subjects with data that do not have a relevant protocol violation (relevant to PK or PD). No data collected for Omeprazole arm since no plasma dipyridamole was expected for this treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Aggrenox Alone BID</title>
            <description>Aggrenox (aspirin/extended release dipyridamole) 25mg/200mg capsules BID (twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Aggrenox BID Plus Omeprazole QD Following Aggrenox Alone</title>
            <description>Aggrenox 25mg/200mg capsules BID plus Omeprazole 40mg QD (once daily) following Aggrenox alone</description>
          </group>
          <group group_id="O3">
            <title>Aggrenox BID Plus Omeprazole QD Following Omeprazole Alone</title>
            <description>Aggrenox 25mg/200mg capsules BID plus Omeprazole 40mg QD (once daily) following Omeprazole alone</description>
          </group>
          <group group_id="O4">
            <title>Omeprazole Alone QD</title>
            <description>Omeprazole 40mg QD (once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Dipyridamole Minimum Concentration (Cmin)</title>
          <description>Minimum measured concentration of dipyridamole in plasma</description>
          <population>The pharmacokinetic data set (PK set) and the pharmacodynamic data set (PD set) include all treated subjects with data that do not have a relevant protocol violation (relevant to PK or PD). No data collected for Omeprazole arm since no plasma dipyridamole was expected for this treatment.</population>
          <units>nanogram/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="679" spread="47.1"/>
                    <measurement group_id="O2" value="723" spread="41.8"/>
                    <measurement group_id="O3" value="713" spread="46.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Aggrenox + Omeprazole following Omeprazole versus Aggrenox alone</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence was established if the 90% confidence interval of the mean ratio fell within the 80 to 125% target range.</non_inferiority_desc>
            <param_type>Percent Mean Ratio</param_type>
            <param_value>105.55</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>97.09</ci_lower_limit>
            <ci_upper_limit>114.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Aggrenox + Omeprazole following Aggrenox versus Aggrenox alone</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence was established if the 90% confidence interval of the mean ratio fell within the 80 to 125% target range.</non_inferiority_desc>
            <param_type>Percent Mean Ratio</param_type>
            <param_value>106.09</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>98.64</ci_lower_limit>
            <ci_upper_limit>114.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inhibition of Platelet Aggregation at 12 Hours Post Dose (IPA12)</title>
        <description>IPA12 equals the platelet aggregation measured 12 hours post dose divided by the platelet aggregation measured at baseline (multiplied by 100).</description>
        <time_frame>7 days</time_frame>
        <population>The pharmacokinetic data set (PK set) and the pharmacodynamic data set (PD set) include all treated subjects with data that do not have a relevant protocol violation (relevant to PK or PD). No data collected for Omeprazole arm since no platelet inhibition was expected for this treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Aggrenox Alone BID</title>
            <description>Aggrenox (aspirin/extended release dipyridamole) 25mg/200mg capsules BID (twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Aggrenox BID Plus Omeprazole QD Following Aggrenox Alone</title>
            <description>Aggrenox 25mg/200mg capsules BID plus Omeprazole 40mg QD (once daily) following Aggrenox alone</description>
          </group>
          <group group_id="O3">
            <title>Aggrenox BID Plus Omeprazole QD Following Omeprazole Alone</title>
            <description>Aggrenox 25mg/200mg capsules BID plus Omeprazole 40mg QD (once daily) following Omeprazole alone</description>
          </group>
          <group group_id="O4">
            <title>Omeprazole Alone QD</title>
            <description>Omeprazole 40mg QD (once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Inhibition of Platelet Aggregation at 12 Hours Post Dose (IPA12)</title>
          <description>IPA12 equals the platelet aggregation measured 12 hours post dose divided by the platelet aggregation measured at baseline (multiplied by 100).</description>
          <population>The pharmacokinetic data set (PK set) and the pharmacodynamic data set (PD set) include all treated subjects with data that do not have a relevant protocol violation (relevant to PK or PD). No data collected for Omeprazole arm since no platelet inhibition was expected for this treatment.</population>
          <units>percent of baseline platelet aggregation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.78" spread="2.53"/>
                    <measurement group_id="O2" value="97.80" spread="3.00"/>
                    <measurement group_id="O3" value="98.11" spread="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Aggrenox + Omeprazole following Omeprazole versus Aggrenox alone</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence was established if the 90% confidence interval of the mean ratio fell within the 80 to 125% target range.</non_inferiority_desc>
            <param_type>Percent Mean Ratio</param_type>
            <param_value>99.38</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>98.80</ci_lower_limit>
            <ci_upper_limit>99.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Aggrenox + Omeprazole following Aggrenox versus Aggrenox alone</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence was established if the 90% confidence interval of the mean ratio fell within the 80 to 125% target range.</non_inferiority_desc>
            <param_type>Percent Mean Ratio</param_type>
            <param_value>99.02</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>98.46</ci_lower_limit>
            <ci_upper_limit>99.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Peak-to-trough Fluctuation (%PTF)</title>
        <description>PTF = 100*((Cmax-Cmin)/Cavg) where Cavg=(AUC0-12)/12.</description>
        <time_frame>7 days</time_frame>
        <population>The pharmacokinetic data set (PK set) and the pharmacodynamic data set (PD set) include all treated subjects with data that do not have a relevant protocol violation (relevant to PK or PD). No data collected for Omeprazole arm since no plasma dipyridamole was expected for this treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Aggrenox Alone BID</title>
            <description>Aggrenox (aspirin/extended release dipyridamole) 25mg/200mg capsules BID (twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Aggrenox BID Plus Omeprazole QD Following Aggrenox Alone</title>
            <description>Aggrenox 25mg/200mg capsules BID plus Omeprazole 40mg QD (once daily) following Aggrenox alone</description>
          </group>
          <group group_id="O3">
            <title>Aggrenox BID Plus Omeprazole QD Following Omeprazole Alone</title>
            <description>Aggrenox 25mg/200mg capsules BID plus Omeprazole 40mg QD (once daily) following Omeprazole alone</description>
          </group>
          <group group_id="O4">
            <title>Omeprazole Alone QD</title>
            <description>Omeprazole 40mg QD (once daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Peak-to-trough Fluctuation (%PTF)</title>
          <description>PTF = 100*((Cmax-Cmin)/Cavg) where Cavg=(AUC0-12)/12.</description>
          <population>The pharmacokinetic data set (PK set) and the pharmacodynamic data set (PD set) include all treated subjects with data that do not have a relevant protocol violation (relevant to PK or PD). No data collected for Omeprazole arm since no plasma dipyridamole was expected for this treatment.</population>
          <units>percent of average hourly plasma conc.</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144" spread="31.8"/>
                    <measurement group_id="O2" value="132" spread="41.4"/>
                    <measurement group_id="O3" value="134" spread="41.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Aggrenox Alone BID</title>
          <description>Aggrenox (aspirin/extended release dipyridamole) 25mg/200mg capsules BID (twice daily)</description>
        </group>
        <group group_id="E2">
          <title>Aggrenox BID Plus Omeprazole QD Following Aggrenox Alone</title>
          <description>Aggrenox 25mg/200mg capsules BID plus Omeprazole 40mg QD (once daily) following Aggrenox alone</description>
        </group>
        <group group_id="E3">
          <title>Omeprazole Alone QD</title>
          <description>Omeprazole 40mg QD (once daily)</description>
        </group>
        <group group_id="E4">
          <title>Aggrenox BID Plus Omeprazole QD Following Omeprazole Alone</title>
          <description>Aggrenox 25mg/200mg capsules BID plus Omeprazole 40mg QD (once daily) following Omeprazole alone</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Other - Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

